Detail

Basic Information Clinical Results Relationship Graph

GTO ID	GTC1347
Trial ID	NCT01085292
Disease	Type 2 Diabetes Mellitus
Altered gene	CCL1
Therapeutic/Target gene	Target gene
Therapy	Aptamer
Treatment	NOX-E36\|Spiegelmer
Phase	Phase1\|Phase2
Recruitment status	Completed
Title	NOX-E36 - A Phase Ib, Multiple Intravenous Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties in Healthy Subjects and Then in Three Groups of Patients With Type 2 Diabetes Mellitus to Compare Three Ascending Dose Regimens in a Double-blind and Placebo-controlled Manner
Year	2010
Country	Germany
Company sponsor	TME Pharma AG
Other ID(s)	SNOXE36C101\|2010-019148-38

Cohort1: healthy volunteers

Administration route	intravenous injection
Dosage	NOX-E36, 0.25 mg/kg, Multiple dose, dosing frequency q2d
Age	Adult, Older_Adult
References	PMID: 30957581

Cohort2: patients with type 2 diabetes mellitus_dose level 1

Administration route	intravenous injection
Dosage	NOX-E36, 0.0625 mg/kg, Multiple dose, dosing frequency q2d
Age	Adult, Older_Adult
References	PMID: 30957581

Cohort3: patients with type 2 diabetes mellitus_dose level 2

Administration route	intravenous injection
Dosage	NOX-E36, 0.125 mg/kg, Multiple dose, dosing frequency q2d
Age	Adult, Older_Adult
References	PMID: 30957581

Cohort4: patients with type 2 diabetes mellitus_dose level 3

Administration route	intravenous injection
Dosage	NOX-E36, 0.25 mg/kg, Multiple dose, dosing frequency q2d
Age	Adult, Older_Adult
References	PMID: 30957581

Overview of Knowledge Graph